Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 98 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 M2\lZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDZNE0yOCEQvF2= MVWwMVQh\A>? M1;sXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkC0NlY4ODJ5OES=
HepG2 Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTXPGwxNTFyIN88US=> NHLMbYMxNTRiZB?= MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1nJclI3PzB{N{i0
HT29 NF;0Oo1HfW6ldHnvckBCe3OjeR?= MVK1NOKhdk1? MVKyOE04OiCq M3vNfIlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=> MoG3NlY4ODJ5OES=
HepG2 MVvGeY5kfGmxbjDBd5NigQ>? NFXBUFE2OMLibl2= MXuyOE04OiCq M2XhZ4lv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhOjUEoHlCpC=> M1PYR|I3PzB{N{i0
HCC827 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzwOU84NjVxMUCgcm0> M3rHdlczyqCq M2LS[mROW09? Mm\C[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? NYDVZXNEOjZ4N{W0PFQ>
A549  NESyRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVqxNE8yPS9{MDDuUS=> Mk\WO|LDqGh? MVzEUXNQ M{jz[oVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk MWeyOlY4PTR6NB?=
NCI-H460  M1\XUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm5NVAwOjBxM{Cgcm0> MWC3NuKhcA>? MXrEUXNQ Mn35[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? NVzG[FJoOjZ4N{W0PFQ>
J89GFP Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP6S25qTE2VT9Mg M17vcmVEPTB;NEmuPFUhyrFiMUKuOlUhdk1? Mlr2NlY2PjN3Nki=
THP89GFP MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXEUXNQyqB? NIPRXWtGSzVyPUG5MlM1KMLzIE[uOFMhdk1? M4DVVFI3PTZ|NU[4
SK-NEP-1 M13EWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\i[mozOC5yMfMAl|ExNjBizszN NHXkU3QzPCCq NEHNdmtFVVORwrC= MlHYTWM2OD15Nj6zOEBvVQ>? MYeyOlE4PjJzOR?=
G401 Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm1NE4xOeLCk{GwMlAh|ryP NVrmeVZCOjRiaB?= NFnMS21FVVORwrC= M4XScWlEPTB;MUSzMlAzKG6P MVGyOlE4PjJzOR?=
SK-NEP-1 M1fqeGNmdGxiVnnhZoltcXS7IFHzd4F6 NH\FZXU2OCCwTR?= MkXNNgKBmzRiZB?= NHn0O5BFVVORwrC= NH;0Sotz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? MorFNlYyPzZ{MUm=
G401 MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVXIO|NsPTBibl2= MnzFNgKBmzRiZB?= NUnWSHlCTE2VT9Mg NXz5WI4yemWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NUX3V|ZGOjZzN{[yNVk>
SK-NEP-1 MmjqRZBweHSxc3nzJGF{e2G7 Mk\yOVAwOTByIH7N NIjGPZgzPCCq M13sXmROW00EoB?= MWPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFzaU2czPjF5NkKxPS=>
G401 MnjtRZBweHSxc3nzJGF{e2G7 M3KyNFUxNzFyMDDuUS=> MkDrNlQhcA>? NFvs[olFVVORwrC= NHm2elZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWP5dnNSOjZzN{[yNVk>
SK-NEP-1 M3GwemZ2dmO2aX;uJGF{e2G7 NEfpe|U2OC9zMECgcm0> M1njVlI1KGh? NHTCeXNFVVORwrC= MVnzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v MlnSNlYyPzZ{MUm=
G401 MmTUSpVv[3Srb36gRZN{[Xl? MWe1NE8yODBibl2= MkjNNlQhcA>? MYrEUXNQyqB? NV3YWIpye2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?= M1PUXVI3OTd4MkG5
SK-NEP-1 NXi1NpJDTnWwY4Tpc44hSXO|YYm= MV21NE8yODBibl2= M{HDWVI1KGh? M1zGdmROW00EoB?= M4rHRolv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh M2rJUVI3OTd4MkG5
G401 NH;lN5ZHfW6ldHnvckBCe3OjeR?= NUDZTnduPTBxMUCwJI5O M1O5UVI1KGh? MY\EUXNQyqB? NYXNTW9[cW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? MXSyOlE4PjJzOR?=
RPMI 8226 MnLWR4VtdCCVdYL2bZZidCCDc4PhfS=> NXK5coRvOi92L{[gcm0> MXm0PQKBkWh? M4XybYlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? MlX0NlYxODB{OUK=
OPM2 NH3RRplE\WyuIGP1dpZqfmGuIFHzd4F6 M4DFPVIwPC94IH7N MkfmOFjjiImq MWfpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp M3G1OFI3ODByMkmy
U266 NVfCdY1XS2WubDDTeZJ3cX[jbDDBd5NigQ>? MXOyM|QwPiCwTR?= NIXrSZI1QOLCiXi= NUX4TlhOcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= M3;ufVI3ODByMkmy
H929 NV7IO|RuS2WubDDTeZJ3cX[jbDDBd5NigQ>? MWWyM|QwPiCwTR?= MXK0PQKBkWh? Mn22bY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? MVqyOlAxODJ7Mh?=
RPMI 8226  MkS3RZBweHSxc3nzJGF{e2G7 NVHqUVhiPOLCiX7N MoXVNlQwPDhiaB?= NESyUJVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NXjKbXFSOjZyMECyPVI>
HCC827 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknmNVAhdk1? NYjmZXExPDhiaB?= MXPEUXNQ MnzP[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB? MmTKNlU6PDR4MUe=
NCI-H23 NHTUWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWixNEBvVQ>? MWq0PEBp NF\2d3RFVVOR Ml;q[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB? M1n4VFI2QTR2NkG3
AML3 NHfrN|ZHfW6ldHnvckBCe3OjeR?= NHHnNWIxNTFizszN NHrx[GQzPMLiaB?= MWjpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1TVV|I2PjF{OUSx
ML-1 NGfv[GRHfW6ldHnvckBCe3OjeR?= MYOwMVEh|ryP M4rueFI1yqCq MUPpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NX7uRZZsOjV4MUK5OFE>
RPMI-8226vr10  NGPpNYtHfW6ldHnvckBCe3OjeR?= M2HE[lAuOSEQvF2= M3SxOVI1yqCq NULD[XUzcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYr4bmVxOjV4MUK5OFE>
ML-1 NF;hNXpHfW6ldHnvckBCe3OjeR?= MXuxJO69VQ>? Mn\lNlTDqGh? Mnr2bY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUA1NW[xbHS= M1nZNlI2PjF{OUSx
RPMI-8226vr10  MlPMSpVv[3Srb36gRZN{[Xl? NWGz[WlFOSEQvF2= MVOyOOKhcA>? MknobY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUAzNjVvZn;s[C=> NH7JcHQzPTZzMkm0NS=>
SK-N-BE (2) NInm[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\KSm1wOjUkgJno M4HNbGlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= NFLDb4kzPTNyOEmxOi=>
SK-N-BE (2), PAN  MK MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rnSVI16oDLaB?= M3nkWmlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= MVuyOVMxQDlzNh?=
SK-N-BE (2), MK  PAN NHTSU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrYUIczPOLCiXi= NGPH[IdKSzVyPUO4Nk4x6oDLwsJihKk1Oy5{IH7N NWjRd5lkOjV|MEi5NVY>
SK-N-AS M2\3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfFc5UzPOLCiXi= MUjJR|UxRTN5LkJihKnDueLCiUKuOEBvVQ>? MlPNNlU{ODh7MU[=
SK-N-DZ MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i1flI16oDLaB?= NVPaT3ZrUUN3ME2xO{4y6oDLwsJihKkxNjRibl2= NX3zTI12OjV|MEi5NVY>
Caki-1 NXTpPHVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;h[FgyOC9{NT:1NEBvVQ>? NWOxOXF2PDhiaB?= Mo\vbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MnrQNlUzPzlzOUG=
ACHN NX;mPZNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnFcY8yOC9{NT:1NEBvVQ>? NVzCXZB3PDhiaB?= MoO2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ M4O2RVI2Ojd7MUmx
769-P MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHtNVAwOjVxNUCgcm0> NXL6OZpJPDhiaB?= NVrRfINNcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny MW[yOVI4QTF7MR?=
786-O  MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DwclExNzJ3L{WwJI5O NHq0NIQ1QCCq NFr2NVZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MWqyOVI4QTF7MR?=
Caki-1 NInUb|ZCeG:ydH;zbZMhSXO|YYm= MWS1NEBvVQ>? NHvwe|E1QCCq Mn\jbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? MYqyOVI4QTF7MR?=
ACHN MkW2RZBweHSxc3nzJGF{e2G7 M3O2eFUxKG6P NF[5UFA1QCCq NEfE[21qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= M{K1SlI2Ojd7MUmx
769-P M3;QcWFxd3C2b4Ppd{BCe3OjeR?= NFLrd242OCCwTR?= Mo\hOFghcA>? MlLHbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? NUK3[IREOjV{N{mxPVE>
786-O  MWfBdI9xfG:|aYOgRZN{[Xl? Mo\DOVAhdk1? NH61TWE1QCCq NVPiOFJPcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= NI\OXIwzPTJ5OUG5NS=>
Caki-1 Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPhRpFFOjVxNUCgcm0> NWPHNlVTPDhiaB?= M{PnXWROW09? MVHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MmrSNlUyPzZ|NUS=
ACHN M{TtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX5NlUwPTBibl2= NFiwWoU1QCCq M3TWZ2ROW09? MknMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= MnnYNlUyPzZ|NUS=
769-P MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzKZpkzPS93MDDuUS=> MnH2OFghcA>? MoK5SG1UVw>? MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MnG1NlUyPzZ|NUS=
Caki-1 M1\IdWNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? M3LwSVUxKG6P Mk\5O{0yPCCm M3;hO2ROW09? MljSd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> NEnj[G0zPTF5NkO1OC=>
ACHN M{jQTmNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? MW[1NEBvVQ>? M3[4[lcuOTRiZB?= NFnyRXlFVVOR MUTzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> MUWyOVE4PjN3NB?=
769-P NWDV[nNyS2:ub375JGZwem2jdHnvckBCe3OjeR?= NUnmb21DPTBibl2= MoPFO{0yPCCm NXTLPJZ5TE2VTx?= MUPzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> MlvxNlUyPzZ|NUS=
Caki-1 MlvTRZBweHSxc3nzJGF{e2G7 MoDPOVAhdk1? NELaems1QCCq NHvu[G9FVVOR MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NYTq[5VwOjVzN{[zOVQ>
ACHN MX3BdI9xfG:|aYOgRZN{[Xl? MnuyOVAhdk1? M13Lc|Q5KGh? NXfXSIpzTE2VTx?= MUPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVyyOVE4PjN3NB?=
769-P M4TYWmFxd3C2b4Ppd{BCe3OjeR?= MYS1NEBvVQ>? NULXW2g6PDhiaB?= M3LSR2ROW09? NEfCdJRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NGfLe3czPTF5NkO1OC=>
MDA-MB-231 NXH0cIFFVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 NUXU[5NtOTEEoH7N M3\pO|PDqGR? Mm[ySG1UVw>? Ml6xZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi MnP1NlQ5OTB2OUe=
BT-549 MWnNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> MmG4NVDDqG6P M1zLSlPDqGR? NX;5WIhRTE2VTx?= NGfLcppidHSncoOgZ4VtdCCvb4LwbI9td2e7wrC= NFnFbXYzPDhzMES5Oy=>
MCF-7  NEnTVXlOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? NFv3eYkyOMLibl2= NGC3UWc{yqCm NUP3doZKTE2VTx?= MWHhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? NV3DXGMyOjR6MUC0PVc>
MCF-7 NEDvWmtHfW6ldHnvckBCe3OjeR?= MXO1MVUxKG6P MXSyOEBp MkXnSG1UVw>? NVrqbYd1emWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>? MkTINlQ{PjZ2MEe=
CTS NEHDT3JCeG:ydH;zbZMhSXO|YYm= MXmw5qCUPDBibl5CpC=> M4[2e|Q5KGh? NYDSU5JicW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXKyOFI1PDR{OR?=
OCI-AML3  MmjHRZBweHSxc3nzJGF{e2G7 MYew5qCUPDBibl5CpC=> NYD6T29KPDhiaB?= NFmyeXNqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVOyOFI1PDR{OR?=
U937 NFXZb2NCeG:ydH;zbZMhSXO|YYm= NFruZYEx6oDVNECgcm3DqA>? NI\kcnc1QCCq MXjpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkXyNlQzPDR2Mkm=
PC3 M1zz[2Fxd3C2b4Ppd{BCe3OjeR?= NXnXXJJXOC1zMECgcm0> MX6yOE81QCCq NFrBdZRqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M2\mNFI1OTZ|MkOw
PC3-AR NWXvNZRISXCxcITvd4l{KEG|c3H5 NH2zbocxNTFyMDDuUS=> NHTOUHQzPC92ODDo M2XCdYlv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWqyOFE3OzJ|MB?=
PC3 NHf3fFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLZRnVCOC1zMECgcm0> NVjFVnpmOjRxNEigbC=> Mk\kbY5lfWOnczDhZ4N2dXWuYYTpc44hd2Zic4XiS|EheG:ydXzheIlwdg>? MlTENlQyPjN{M{C=
PC3-AR M{\wTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHBR5IxOC1zMECgcm0> M3m4dlI1NzR6IHi= NYnNXXFIcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiC2aHWgS|JOKHCqYYPl NIi4OGozPDF4M{KzNC=>
PC3 M4rkT2Z2dmO2aX;uJGF{e2G7 MmHPNE0yODBibl2= MmD6NlQhcA>? M2O1ZpN2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu NVO0NYlDOjRzNkOyN|A>
PC3-AR NHn4OFNHfW6ldHnvckBCe3OjeR?= M1mzUlAuOTByIH7N M1PHVVI1KGh? M2XvfpN2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu MVyyOFE3OzJ|MB?=
OS-RC-2 NHvCbZpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEnsVlkxNTFyMECgcm0> NHG3[lYzPC92OD:3NkBp M2W1d2ROW09? M3TlUoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MX2yOFE1PDd|Nx?=
OS-RC-2 NUTzZWlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHvOVAhdk1? NUXXc3RvPDhiaB?= NFfsbXBFVVOR MkPPbY5lfWOnczDHNk9OKGG{cnXzeC=> Mlq1NlQyPDR5M{e=
OS-RC-2 NXvH[3c2SXCxcITvd4l{KEG|c3H5 NX;mbIt4PTBibl2= NUHOXI5PPDhiaB?= MYXEUXNQ NX3JVolOcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NYHkSpdvOjRzNES3N|c>
SK-N-AS MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVew5qCUQDBibl2= MW[0PEBp NGDFW3ZKSzVyPUK3MlQhdk1? MoDmNlQxQTh5OUm=
SK-N-DZ NWLmdnBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XBUVDjiJN6MDDuUS=> MlraOFghcA>? NEfmRndKSzVyPUKxMlkhdk1? MnXKNlQxQTh5OUm=
SK-N-SH MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuw5qCUQDBibl2= Mkn0OFghcA>? NI\kcIhKSzVyPUeyMlMhdk1? M{\OSlI1ODl6N{m5
SK-N-BE M4n4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWw5qCUQDBibl2= M4rsVFQ5KGh? NWfZVJhMUUN3ME23OU41KG6P NH76T4EzPDB7OEe5PS=>
SK-N-AS MWPBdI9xfG:|aYOgRZN{[Xl? M2fiRVDjiJN6MDDuUS=> M{TlflQ5KGh? NEKyWXJxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> MV:yOFA6QDd7OR?=
SK-N-DZ NXi4XYxUSXCxcITvd4l{KEG|c3H5 NVO0NINGOOLCk{iwJI5O MnTyOFghcA>? NX3xdY5UeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v M13iVlI1ODl6N{m5
SK-N-SH MVTBdI9xfG:|aYOgRZN{[Xl? NETvNFQx6oDVNECgcm0> MWq0PEBp M1\PVZBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> MnHTNlQxQTh5OUm=
SK-N-BE MlrHRZBweHSxc3nzJGF{e2G7 M1z5ZVDjiJN2MDDuUS=> MXu0PEBp NVrufnBFeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v MYGyOFA6QDd7OR?=
SK-N-AS NGmyb|BHfW6ldHnvckBCe3OjeR?= MV6w5qCUQDBibl2= MYi0PEBp MkLzbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MYSyOFA6QDd7OR?=
SK-N-DZ MYDGeY5kfGmxbjDBd5NigQ>? MmrnNQKBmzhyIH7N MlvjOFghcA>? MlG4bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MnXUNlQxQTh5OUm=
SK-N-SH NVjwb4hETnWwY4Tpc44hSXO|YYm= Mn;BNQKBmzRyIH7N M3rhb|Q5KGh? NFjjWHRqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR NHH6RYIzPDB7OEe5PS=>
SK-N-BE M1;s[mZ2dmO2aX;uJGF{e2G7 Mne4NQKBmzRyIH7N NX\leJNpPDhiaB?= NXfEW3o2cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MVmyOFA6QDd7OR?=
HCC-LM3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKxMVExODBibl2= MUSyOE81QC95MjDo MljQSG1UVw>? MVvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MW[yOFA6Ozl3Nh?=
HepG2 MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jQWFEuOTByMDDuUS=> MVOyOE81QC95MjDo M4DrN2ROW09? MmHibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnK5NlQxQTN7NU[=
SMMC-7721 M2r0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrqXYwyNTFyMECgcm0> NYfCVGJ[OjRxNEivO|IhcA>? NUTCdItXTE2VTx?= MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWmyOFA6Ozl3Nh?=
HCC-LM3 NXXMWlBSSXCxcITvd4l{KEG|c3H5 NULoT5pzPTBibl2= M{i2T|Q5KGh? MlTiSG1UVw>? NFHER|NqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? NX32U29tOjRyOUO5OVY>
HepG2 M{nMcGFxd3C2b4Ppd{BCe3OjeR?= NWrLWFF2PTBibl2= Mny1OFghcA>? MUTEUXNQ NGLiUYJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? NFHzdlUzPDB7M{m1Oi=>
SMMC-7721 MYfBdI9xfG:|aYOgRZN{[Xl? NUe1XGVmPTBibl2= MVO0PEBp MmjkSG1UVw>? MYfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> MXiyOFA6Ozl3Nh?=
HCC-LM3 MmHwSpVv[3Srb36gRZN{[Xl? NUf0UmF2PTBxMUCwJI5O NEPK[5EzPCCq NYj5eIZHTE2VTx?= MW\k[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi Mn3UNlQxQTN7NU[=
HepG2 MYPGeY5kfGmxbjDBd5NigQ>? NVLQcXF6PTBxMUCwJI5O M1rB[|I1KGh? M2f6[mROW09? MWHk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi NVHTNmJUOjRyOUO5OVY>
SMMC-7721 NFfZPWdHfW6ldHnvckBCe3OjeR?= MkHFOVAwOTByIH7N NH34SlUzPCCq M3XDN2ROW09? M2fL[oRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= MUWyOFA6Ozl3Nh?=
HCC-LM3 NUW5O2Z5TnWwY4Tpc44hSXO|YYm= NGTaNHU2OC9zMECgcm0> MnPSNlQhcA>? NF;SV5lFVVOR NUL6OW11\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NGO2TZkzPDB7M{m1Oi=>
HepG2 MnH3SpVv[3Srb36gRZN{[Xl? MlrKOVAwOTByIH7N Mm\UNlQhcA>? NFHPb5JFVVOR NHnpRoRld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w M2jrUlI1ODl|OUW2
SMMC-7721 Mn3QSpVv[3Srb36gRZN{[Xl? NGnhPY42OC9zMECgcm0> MoC0NlQhcA>? M1[3OWROW09? M4O2WYRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? MVeyOFA6Ozl3Nh?=
FaDu Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxNFDjiIWwTR?= NWjUOYtKQC9zMD:xNkBp NFLmR|BlcXOybHH5[YQh[SC|aXfubYZq[2GwdDDhcoQheHKxbH;u[4VlKEd{L12gZZJz\XO2IHH0JFgh[W6mIEGy5qCGcCCyb4P0JJJmdGWjc3W= MYeyOFAzPjR6Mh?=
FaDu MonvSpVv[3Srb36gRZN{[Xl? Moi1NVAx6oDHbl2= MVyyM|QwQC9zMjDo M4H6cYlv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w M{KwbFI1ODJ4NEiy
PC-3  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP3VpIxNTFyIN88US=> NUW5NYNEOjRxNEivO|IhcA>? M2nIUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2TSV|I{QTlzMkG2
LNCaP NXLZclJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWwNE02KM7:TR?= M1zJdVI1NzR6L{eyJIg> NXO4ZWt{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnLPNlM6QTF{MU[=
RWPE-1  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjR[XoxNTJyIN88US=> NH:w[oMzPC92OD:3NkBp NHS3dnRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGnIc|gzOzl7MUKxOi=>
Capan-1 NGn2PWZHfW6ldHnvckBCe3OjeR?= NVy4bJNCOjVxNUCvNVAxKG6P NF7KS4M5NzJ2L{S4JIg> M4PYb2ROW09? MnXk[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= MmjLNlM6OjJ6OE[=
L3.6pl NYPo[HdpTnWwY4Tpc44hSXO|YYm= NETNOGUzPS93MD:xNFAhdk1? Mn3KPE8zPC92ODDo MknFSG1UVw>? MULkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p M3vIZlI{QTJ{OEi2
CFPAC-1  NWfUXZNHTnWwY4Tpc44hSXO|YYm= NVrFUItKOjVxNUCvNVAxKG6P MnnqPE8zPC92ODDo NIe1N3hFVVOR Mnq4[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= NG\RRnIzOzl{Mki4Oi=>
Capan-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDVU4hmOjVxNUCvNVAxKG6P M2qySlQ5KGh? MmjtSG1UVw>? M2XTO5Jm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVuyN|kzOjh6Nh?=
L3.6pl NYXPVlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PpbVI2NzVyL{GwNEBvVQ>? NH;yUJM1QCCq MYTEUXNQ NEXlOoVz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkHJNlM6OjJ6OE[=
CFPAC-1  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGyOU82OC9zMECgcm0> NWTrbHhyPDhiaB?= MV\EUXNQ MX;y[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mn63NlM6OjJ6OE[=
Capan-1 M{HuU2Fxd3C2b4Ppd{BCe3OjeR?= NES0PFAzPS93MD:xNFAhdk1? M{HVelQ5KGh? NVe4VZJLTE2VTx?= MY\pcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVmyN|kzOjh6Nh?=
L3.6pl MXXBdI9xfG:|aYOgRZN{[Xl? M1fFeVI2NzVyL{GwNEBvVQ>? NWjZZlR4PDhiaB?= NF;KTIVFVVOR NYj1WJMzcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUGyN|kzOjh6Nh?=
CFPAC-1  MUXBdI9xfG:|aYOgRZN{[Xl? M1TpOFI2NzVyL{GwNEBvVQ>? NYXTWWJqPDhiaB?= MWrEUXNQ MUfpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVjacYdlOjN7MkK4PFY>
HN22 NHj6eWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nRXVAuOjBibl2= NVfxOIlFOjRxNEigbC=> M36xbWROW09? NVvtR4x5cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? MWiyN|g4PzJ|NR?=
HSC4  NHzsVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHpNGhsOC1{MDDuUS=> MV2yOE81QCCq M1rFUmROW09? MX3pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy Mn;0NlM5Pzd{M{W=
HN22 MXHBdI9xfG:|aYOgRZN{[Xl? MYewMVIxKG6P MV60PEBp M3fweGROW09? NEnpbGNqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NES1PY8zOzh5N{KzOS=>
HSC4  NVfFN4UxSXCxcITvd4l{KEG|c3H5 Mn\xNE0zOCCwTR?= M{jCOVQ5KGh? MmP0SG1UVw>? NVr6cFNRcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NUjsb4pZOjN6N{eyN|U>
HN22 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOwMVIxKG6P Mn3rOFghcA>? MUnEUXNQ M3Gybolv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> NWW1PW1mOjN6N{eyN|U>
HSC4  NUDkRWduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7pXFN3OC1{MDDuUS=> MVW0PEBp M1XZO2ROW09? NGDPV21qdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> M2TmZlI{QDd5MkO1
HN22 NYDBR3VlTnWwY4Tpc44hSXO|YYm= NYPJWZc4OC1{MDDuUS=> NVPpfZdDPDhiaB?= M3\RbGROW09? M3;GdZN2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=> M2WxPVI{QDd5MkO1
HSC4  NEf6dZlHfW6ldHnvckBCe3OjeR?= NXXtRmJGOC1{MDDuUS=> MmDVOFghcA>? NFOzbG9FVVOR NYe0TIp1e3WycILld5NmeyCVcEGg[ZhxemW|c3nvcuKh NY[4RpByOjN6N{eyN|U>
Cal62 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTN|INMxJFQhdk1? NXXuTnVpOjN6MkSwOlQ>
Hth7 NH\KRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL5TWM2OD1zNTFCtUAzKG6P M1LmSFI{QDJ2ME[0
Hth83 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzMTWM2OD1|NDFCtUA2KG6P NG\rPHQzOzh{NEC2OC=>
C643 NIP3PVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTdzINMxJFExKG6P NH\zcmozOzh{NEC2OC=>
SW1736 M2nZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j5ZWlEPTB;M{WgxtEhQCCwTR?= M{fzUlI{QDJ2ME[0
T241 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonoTWM2OD14NTFCtUA4KG6P NFPTTpczOzh{NEC2OC=>
T351 MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHLTWM2OD13MDFCtUAyOCCwTR?= MWSyN|gzPDB4NB?=
BHP2-7 M3ToTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvRZYh6UUN3ME2zO{DDuSB4IH7N MVWyN|gzPDB4NB?=
T238 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLGTmczUUN3ME2xMFUxOCEEsTCyNFAhdk1? MYOyN|gzPDB4NB?=
HCT8 NWTRR2s6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvxWZNqPzJiaB?= NYWzOIJVTE2VTx?= MYfJR|UxRTF{LkpihKnDueLCiUGuPUBvVQ>? MnSzNlMzQTl|OEi=
H630 M4Tncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXy3NkBp MnL0SG1UVw>? MYPJR|UxRTF{LkVihKnDueLCiUOuNUBvVQ>? MUWyN|I6QTN6OB?=
cH630 5-FU-res NITafWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\Ee2s4OiCq M3XuN2ROW09? MkLJTWM2OD1zNT615qCKyrIkgJmxMlIhdk1? NGO0WWUzOzJ7OUO4PC=>
HCT116 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLWO|IhcA>? MUDEUXNQ MkToTWM2OD1zMD635qCKyrIkgJmyMlIhdk1? MViyN|I6QTN6OB?=
HCT116 p53−/− MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjFO|IhcA>? NYH5dnRZTE2VTx?= NU\Kb3V3UUN3ME24MlbjiIoEsfMAjVEvPyCwTR?= NIrtVXUzOzJ7OUO4PC=>
dHCT116 p21−/− MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\LO|IhcA>? MYrEUXNQ M{TI[WlEPTB;NT655qCKyrIkgJmxMlMhdk1? MXOyN|I6QTN6OB?=
HT29 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXi3NkBp MW\EUXNQ MWXJR|UxRTF4LkRihKnDueLCiUKuN{BvVQ>? MX[yN|I6QTN6OB?=
LoVo NVTnSnh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnOUJBRPzJiaB?= MWDEUXNQ M{C5SGlEPTB;NT6x5qCKyrIkgJmwMlYhdk1? NXXMWFdxOjN{OUmzPFg>
RKO NELk[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVe3NkBp M1HZe2ROW09? NES0dXRKSzVyPUeuPgKBkcLz4pEJNk4zKG6P NE\nTnMzOzJ7OUO4PC=>
SW480 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPBbWM4PzJiaB?= NFLLUG1FVVOR MVHJR|UxRTF5LkZihKnDueLCiUCuPEBvVQ>? MUKyN|I6QTN6OB?=
eSW620 Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnKO|IhcA>? M3Huc2ROW09? MYfJR|UxRTlwMfMAjeKy6oDLMj6xJI5O NEXHNFAzOzJ7OUO4PC=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID